 |
| Image credit University of Colorado news |
CANCER DIGEST – Dec. 10, 2022 – A new study of pancreatic cancer treatments showed that patients who received chemotherapy before and after surgery survived longer compared to patients who didn't have the chemo. The findings were published in the Dec. 8, 2022 American Medical Association Association’s JAMA Oncology
Led by Marco Del Chiaro, MD, of the University of Colorado Department of Surgery and co-author Toshitaka Sugawara, MD, PhD, the study analyzed outcomes data from a nationwide database of 888 pancreatic cancer patients treated between 2010 and 2018.
They found that patients treated with chemotherapy before and after surgery survived 27 months compared to 21 months for patients who did not receive chemotherapy. This was the case for all patients regardless of whether the cancer had spread to lymph nodes, or the status of the margin of tissue around the surgical area.
Pancreatic cancer remains one of the deadliest forms of cancer. In general, 5-year survival rate for people with pancreatic cancer in the United States is 11 percent, meaning only 11 of 100 people survive five years after diagnosis. This study shows that adding chemotherapy to those patients whose tumors are eligible for surgery might extend survival another six months versus not adding chemotherapy.
“The success of adjuvant chemotherapy used to be unclear, with varied data available for doctors to consider," said Del Chiaro in a press release. "Our study suggests that adjuvant chemotherapy after surgery should be implemented no matter the biological stage of the cancer.”
No comments:
Post a Comment